文献速递关节外科

氨甲环酸在有静脉血栓栓塞史患者全关节置换术中安全

Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty.
PubMed 文献 · J Bone Joint Surg Am · 2023-11-15

该研究基于Premier医疗数据库2015至2021年初次择期全关节置换术患者,识别有静脉血栓栓塞史的高风险队列共70,759例,其中46,074例(65.1%)接受氨甲环酸(TXA),24,685例(34.9%)未接受。多变量回归控制混杂后,TXA组肺栓塞、卒中、心肌梗死风险与未接受TXA组相似,输血和90天再入院风险降低。结论提示TXA在有静脉血栓栓塞史的选择性高风险患者中可安全使用。

要点

  • 有静脉血栓栓塞史的全关节置换术患者中,65.1%接受了TXA。
  • TXA组肺栓塞风险与未接受TXA组相似(调整OR 0.90,95%CI 0.79-1.02,p=0.097)。
  • TXA组输血风险降低(调整OR 0.42,95%CI 0.38-0.46,p<0.001)。

核心结论

  • 在有静脉血栓栓塞史的患者中,使用TXA与术后肺栓塞、卒中、心肌梗死风险增加无关。
  • 接受TXA的患者输血和再入院风险降低。
  • 该证据提示TXA可在选择性的高风险患者中安全使用。

研究设计与样本

  • 基于Premier医疗数据库的回顾性研究,纳入2015至2021年初次择期全关节置换术患者。
  • 有静脉血栓栓塞史(肺栓塞或深静脉血栓)的患者构成高风险队列,共70,759例。
  • 比较高风险队列中接受TXA者(46,074例,65.1%)与未接受TXA者(24,685例,34.9%)的术后结局。
  • 采用单变量回归和多变量回归控制潜在混杂因素。

主要发现

  • TXA组与未接受TXA组肺栓塞风险相似(调整OR 0.90,95%CI 0.79-1.02,p=0.097)。
  • TXA组与未接受TXA组卒中风险相似(调整OR 0.97,95%CI 0.69-1.37,p=0.867)。
  • TXA组与未接受TXA组心肌梗死风险相似(调整OR 0.93,95%CI 0.69-1.24,p=0.614)。
  • TXA组输血风险低于未接受TXA组(调整OR 0.42,95%CI 0.38-0.46,p<0.001)。
  • TXA组90天再入院风险低于未接受TXA组(调整OR 0.87,95%CI 0.80-0.94,p<0.001)。

临床怎么用

  • 作者认为,该证据提示TXA可在选择性的有静脉血栓栓塞史高风险患者中安全使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) is increasingly utilized during total knee arthroplasty (TKA) and total hip arthroplasty (THA) to decrease blood loss; however, there are concerns with regard to potential thromboembolic complications, particularly in high-risk patients. This study sought to define a subset of patients at elevated risk for thromboembolic complications following total joint arthroplasty (TJA) and to compare postoperative outcomes between patients who received TXA and those who did not. METHODS: Patients who underwent primary, elective TJA from 2015 to 2021 were identified in the Premier Healthcare Database. Patients with a history of venous thromboembolism, defined as a history of pulmonary embolism or deep vein thrombosis, were identified and formed the high-risk cohort. Patient demographic characteristics, hospital factors, patient comorbidities, antithrombotic medication use, perioperative blood transfusion, and 90-day complications were assessed and compared between patients who received TXA and those who did not. Univariate regression and multivariable regression were performed to account for potential confounders. RESULTS: The high-risk cohort comprised 70,759 patients who underwent TJA, of whom 46,074 (65.1%) received TXA and 24,685 (34.9%) did not. After controlling for confounding factors, patients in the TXA cohort had similar risks of pulmonary embolism (adjusted odds ratio [OR], 0.90 [95% confidence interval (CI), 0.79 to 1.02]; p = 0.097), stroke (adjusted OR, 0.97 [95% CI, 0.69 to 1.37]; p = 0.867), and myocardial infarction (adjusted OR, 0.93 [95% CI, 0.69 to 1.24]; p = 0.614) compared with patients who did not receive TXA. Patients who received TXA demonstrated decreased risks of transfusion (adjusted OR, 0.42 [95% CI, 0.38 to 0.46]; p < 0.001) and 90-day readmission (adjusted OR, 0.87 [95% CI, 0.80 to 0.94]; p < 0.001). CONCLUSIONS: TXA utilization was not associated with an increased risk of postoperative pulmonary embolism, stroke, or myocardial infarction in patients with a history of venous thromboembolism. Furthermore, patients who received TXA had a decreased risk of transfusion and readmission. This evidence suggests that TXA may be safely utilized among select high-risk patients. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Richardson MK, Liu KC, Mayfield CK, et al. Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty. J Bone Joint Surg Am. 2023. PMID: 37967163. doi:10.2106/JBJS.23.00254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。